Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma

Recruiting

Phase 2

Zanzalintinib & PembrolizumabPhase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT07283731

Conditions

Phase 2

Zanzalintinib

Pembrolizumab

Advanced/Metastatic

Soft-Tissue Sarcoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Zanzalintinib

Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-05-18. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-04-17.